MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03936cam a2200337 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
21050314 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
ZW-GwMSU |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20211129082554.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
190701s2019 enka b 001 0 eng c |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2019944910 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780128137963 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0128137967 |
| 040 ## - CATALOGING SOURCE |
|---|
| Language of cataloging |
English |
| Transcribing agency |
MSULIB |
| Description conventions |
rda |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
QH599 CHR |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Chromatin signaling and neurological disorders / |
| Statement of responsibility, etc |
edited by Olivier Binda. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Name of producer, publisher, distributor, manufacturer |
Academic Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2019 |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
©2019 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xix, 358 pages : |
| Other physical details |
Illustrations (coloured); |
| Dimensions |
24 cm. |
| 336 ## - CONTENT TYPE |
|---|
| content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| media type term |
unmediated |
| media type code |
n |
| source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| carrier type term |
volume |
| carrier type code |
nc |
| source |
rdacarrier |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Translational epigenetics series ; |
| Volume number/sequential designation |
v. 12 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Front Cover; Chromatin Signaling and Neurological Disorders; Translational Epigenetics Series; Chromatin Signaling and Neurological Disorders; Copyright; Contents; Contributors; Preface; Chromatin and epigenetics; Chromatin signaling and neurological diseases; References; 1 -- Chromatin and epigenetic signaling pathways; 1.1 Chromatin signaling and epigenetics; 1.2 Chromatin organization; 1.3 Histone posttranslational modifications and the histone code; 1.4 Functions of histone posttranslational modifications; 1.5 DNA methylation; 1.6 Writers, erasers, and readers; 1.6.1 Histone writers; 1.6.2 DNA writers1.6.3 Histone erasers; 1.6.4 DNA erasers; 1.6.5 Histone readers; 1.6.6 DNA readers; 1.7 Modification cross talk; 1.8 Effects of metabolism on histone and DNA modifications; 1.9 Epigenetic inheritance; 1.10 Summary; References; 1 -- Neurodegenerative disorders; 2 -- Into the unknown: chromatin signaling in spinal muscular atrophy; 2.1 Spinal muscular atrophy: prevalence, genetic basis, clinical features, and pathogenesis; 2.2 The survival motor neuron protein: localization, structure, and function; 2.3 Epigenetic landscape in spinal muscular atrophy pathogenesis |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
2.4 Targeting epigenetic factors as potential therapeutics in spinal muscular atrophy2.4.1 Histone deacetylase inhibitors as regulators of the survival motor neuron gene; 2.4.2 The nonspecific effect of histone deacetylase inhibitors; 2.4.3 The potential protective effect of histone deacetylase inhibitors in the pathogenesis of spinal muscular atrophy; 2.5 Conclusion; Acronyms and abbreviations; Acknowledgments; References; 3 -- Charcot-Marie-Tooth disease; 3.1 Introduction; 3.2 Epigenetic regulation of Schwann cell development; 3.3 Epigenetic regulation of dosage-sensitive genes; 3.4 Epigenetic regulators targeted by CMT mutations3.4.1 DNMT1; 3.4.2 LMNA; 3.4.3 SYNE1; 3.4.4 MED25; 3.4.5 SETX; 3.4.6 MORC2; 3.4.7 PRDM12; 3.5 Novel mechanisms for CMT mutations; 3.6 Summary; Acknowledgments; References; 4 -- Epigenetic mechanisms in Huntington's disease; 4.1 Introduction; 4.2 Huntington's disease; 4.2.1 Neuropathology of HD; 4.3 Transcriptional dysregulation in HD; 4.4 Altered epigenetic marks in HD; 4.4.1 Histone modifications; 4.4.1.1 Histone acetylation; 4.4.1.2 Histone acetylation alterations in HD; 4.4.1.3 Histone methylation; 4.4.1.4 Histone methylation changes in HD; 4.4.1.5 Histone phosphorylation4.4.1.6 Histone phosphorylation and HD; 4.4.1.7 Histone ubiquitination; 4.4.1.8 Altered histone ubiquitination in HD; 4.4.2 DNA methylation; 4.4.3 DNA methylation changes in HD; 4.4.3.1 Global DNA methylation changes; 4.4.3.2 Gene-specific DNA methylation changes; 4.4.3.3 Implicating DNA methylation enzymes; 4.5 Epigenetic-based therapies; 4.5.1 HDAC inhibitors as a treatment for HD; 4.5.2 Methylation-inhibiting drugs; 4.6 Concluding remarks; 4.7 Abbreviations; References; 5 -- The epigenetics of multiple sclerosis |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Chromatin. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Nervous system |
| General subdivision |
Diseases. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Binda, Olivier, |
| Relator term |
editor. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Translational epigenetics series ; |
| Volume number/sequential designation |
v. 12. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Book |